Idarucizumab

Idarucizumab is a Fab fragment of a humanized monoclonal antibody designed specifically to reverse the anticoagulant effects of dabigatran (Pradaxa), a direct oral thrombin inhibitor used for stroke prevention in atrial fibrillation and treatment/prevention of venous thromboembolism. Mechanism: Idarucizumab binds free and thrombin-bound dabigatran with an affinity approximately 350 times greater than dabigatran's affinity for thrombin, effectively sequestering the drug and neutralizing its anticoagulant activity within minutes. Unlike andexanet alfa (used for factor Xa inhibitors), idarucizumab has no intrinsic procoagulant or anticoagulant activity itself, making it a targeted, specific reversal agent. Clinical indications include: (1) life-threatening or uncontrolled bleeding in patients on dabigatran, and (2) emergency surgery/urgent procedures requiring rapid reversal of anticoagulation. Administered intravenously as two 2.5 g doses given no more than 15 minutes apart. Onset of action is rapid, with reversal of anticoagulant effect typically occurring within minutes, as demonstrated in the RE-VERSE AD trial. Important considerations: reversal is specific to dabigatran only and has no effect on other anticoagulants (e.g., warfarin, factor Xa inhibitors, heparin). After administration, patients remain at risk for thrombotic events related to their underlying condition, and anticoagulation should be restarted when clinically appropriate. Monitoring of coagulation parameters (e.g., dilute thrombin time, ecarin clotting time) can help assess dabigatran reversal, though clinical judgment is paramount. This is a high-yield topic for Step 1/Step 2 given its relevance to emergency medicine, pharmacology, and hematology, especially in questions about anticoagulant reversal agents (compare/contrast with vitamin K for warfarin, protamine for heparin, and andexanet alfa for factor Xa inhibitors).